TY - JOUR
T1 - Survival in response to multimodal therapy in anaplastic thyroid cancer
AU - Prasongsook, Naiyarat
AU - Kumar, Aditi
AU - Chintakuntlawar, Ashish V.
AU - Foote, Robert L.
AU - Kasperbauer, Jan
AU - Molina, Julian
AU - Garces, Yolanda
AU - Ma, Daniel
AU - Neben Wittich, Michelle A.
AU - Rubin, Joseph
AU - Richardson, Ronald
AU - Morris, John
AU - Hay, Ian
AU - Fatourechi, Vahab
AU - McIver, Bryan
AU - Ryder, Mabel
AU - Thompson, Geoffrey
AU - Grant, Clive
AU - Richards, Melanie
AU - Sebo, Thomas J.
AU - Rivera, Michael
AU - Suman, Vera
AU - Jenkins, Sarah M.
AU - Smallridge, Robert C.
AU - Bible, Keith C.
N1 - Publisher Copyright:
Copyright © 2017 Endocrine Society.
PY - 2017
Y1 - 2017
N2 - Context: Historical outcomes in anaplastic thyroid cancer (ATC) have been dismal. Objective: To determine whether an initial intensive multimodal therapy (MMT) is associated with improved ATC survival. Design: MMT was offered to all patients with newly diagnosed ATC treated at the Mayo Clinic from 2003 through 2015; MMT vs care with palliative intent (PI) was individualized considering clinical status and patient preferences. Outcomes were retrospectively analyzed by American Joint Committee on Cancer stage and treatments compared with patient cohort data from 1949 through 1999. Patients: Forty-eight patients (60% male; median age, 62 years); 18 treated with PI, 30 with MMT. Main Outcome Measure: Overall survival (OS) and progression-free survival determined by Kaplan- Meier method. Results: Median OS and 1-year survival for the later cohort were 9 months [95% confidence interval (CI), 4 to 22 months] and 42% (95% CI, 28% to 56%) vs 3 months and 10% for the earlier cohort. Median OS was 21 months compared with 3.9 months in the pooled MMT vs PI groups for the later cohort [hazard ratio (HR), 0.32; P = 0.0006]. Among only patients in the later cohort who had stage IVB disease, median OS was 22.4 vs 4 months (HR, 0.12; 95% CI, 0.03 to 0.44; P = 0.0001), with 68% vs 0% alive at 1 year (MMT vs PI). Among patients with stage IVC cancer, OS did not differ by therapy. Conclusion:MMTappears to convey longer survival in ATC among patients with stage IVA/B disease.
AB - Context: Historical outcomes in anaplastic thyroid cancer (ATC) have been dismal. Objective: To determine whether an initial intensive multimodal therapy (MMT) is associated with improved ATC survival. Design: MMT was offered to all patients with newly diagnosed ATC treated at the Mayo Clinic from 2003 through 2015; MMT vs care with palliative intent (PI) was individualized considering clinical status and patient preferences. Outcomes were retrospectively analyzed by American Joint Committee on Cancer stage and treatments compared with patient cohort data from 1949 through 1999. Patients: Forty-eight patients (60% male; median age, 62 years); 18 treated with PI, 30 with MMT. Main Outcome Measure: Overall survival (OS) and progression-free survival determined by Kaplan- Meier method. Results: Median OS and 1-year survival for the later cohort were 9 months [95% confidence interval (CI), 4 to 22 months] and 42% (95% CI, 28% to 56%) vs 3 months and 10% for the earlier cohort. Median OS was 21 months compared with 3.9 months in the pooled MMT vs PI groups for the later cohort [hazard ratio (HR), 0.32; P = 0.0006]. Among only patients in the later cohort who had stage IVB disease, median OS was 22.4 vs 4 months (HR, 0.12; 95% CI, 0.03 to 0.44; P = 0.0001), with 68% vs 0% alive at 1 year (MMT vs PI). Among patients with stage IVC cancer, OS did not differ by therapy. Conclusion:MMTappears to convey longer survival in ATC among patients with stage IVA/B disease.
UR - http://www.scopus.com/inward/record.url?scp=85038234081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038234081&partnerID=8YFLogxK
U2 - 10.1210/jc.2017-01180
DO - 10.1210/jc.2017-01180
M3 - Article
C2 - 29029287
AN - SCOPUS:85038234081
SN - 0021-972X
VL - 102
SP - 4506
EP - 4514
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 12
ER -